Researchers led by Alzua and colleagues reported a panel of human monoclonal antibodies that potently neutralize clade 2.3.4.4b H5N1 hemagglutinin. Published in Nature Communications, the work maps epitopes and defines mechanisms that achieved high neutralization breadth. The team used structural and functional assays to characterize antibody binding and cross‑clade activity, offering candidates for therapeutic development and templates for improved immunogen design. Authors note implications for stockpiling and rapid-response biologics against avian influenza strains with zoonotic potential. Translational next steps include in vivo efficacy, manufacturability assessment, and regulatory planning for emergency use. The antibodies also provide tools for serologic surveillance and vaccine antigen selection.